|
1
|
Robert-Koch Institut. The Federal Health
Monitoring-Prostate Diseases. Robert Kock-Institut; Berlin: pp.
362007
|
|
2
|
Eisenberg DP, Carpenter SG, Adusumilli PS,
Chan MK, Hendershott KJ, Yu Z and Fong Y: Hyperthermia potentiates
oncolytic herpes viral killing of pancreatic cancer through a heat
shock protein pathway. Surgery. 148:325–334. 2010.
|
|
3
|
Dendreon Press Release: FDA Approves
PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer.
http://http://investor.dendreon.com/releasedetail.cfm?ReleaseID=533434.
Accessed August 7, 2013
|
|
4
|
Kantoff PW, Higano CS, Shore ND, Berger
ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims
RB, Xu Y, Frohlich MW and Schellhammer PF; IMPACT study
investigators. Sipuleucel-T immunotherapy for castration-resistant
prostate cancer. N Engl J Med. 363:411–422. 2010.
|
|
5
|
Draube A, Klein-González N, Mattheus S,
Brillant C, Hellmich M, Engert A and von Bergwelt-Baildon M:
Dendritic cell based tumor vaccination in prostate and renal cell
cancer: a systematic review and meta-analysis. PLoS One.
6:e188012011.
|
|
6
|
Fournier P, Bian H, Szeberényi J and
Schirrmacher V: Analysis of three properties of Newcastle disease
virus for fighting cancer: tumor-selective replication, antitumor
cytotoxicity, and immunostimulation. Methods Mol Biol. 797:177–204.
2012.
|
|
7
|
Hildebrandt B, Wust P, Ahlers O, Dieing A,
Sreenivasa G, Kerner T, Felix R and Riess H: The cellular and
molecular basis of hyperthermia. Crit Rev Oncol Hematol. 43:33–56.
2002.
|
|
8
|
Rao W, Deng ZS and Liu J: A review of
hyperthermia combined with radiotherapy/chemotherapy on malignant
tumors. Crit Rev Biomed Eng. 38:101–116. 2010.
|
|
9
|
Schirrmacher V, Fournier P and Schlag P:
Autologous tumor cell vaccines for post-operative active-specific
immunotherapy of colorectal carcinoma: long-term patient survival
and mechanism of function. Expert Rev Vaccines. 13:117–130.
2014.
|
|
10
|
Gulley JL, Madan RA and Schlom J: Impact
of tumour volume on the potential efficacy of therapeutic vaccines.
Curr Oncol. 18:e150–e157. 2011.
|
|
11
|
Wilt TJ, Brawer MK, Jones KM, et al:
Prostate Cancer Intervention versus Observation Trial (PIVOT) Study
Group: Radical prostatectomy versus observation for localized
prostate cancer. N Engl J Med. 367:203–213. 2012.
|
|
12
|
Chang E, Chalikonda S, Friedl J, Xu H,
Phan GQ, Marincola FM, Alexander HR and Bartlett DL: Targeting
vaccinia to solid tumors with local hyperthermia. Hum Gene Ther.
16:435–444. 2005.
|
|
13
|
Workenhe ST and Mossman KL: Oncolytic
virotherapy and immunogenic cancer cell death: sharpening the sword
for improved cancer treatment strategies. Mol Ther. 22:251–256.
2014.
|
|
14
|
Hou W, Zhang Q, Yan Z, Chen R, Zeh HJ III,
Kang R, Lotze MT and Tang D: Strange attractors: DAMPs and
autophagy link tumor cell death and immunity. Cell Death Dis.
4:e9662013.
|
|
15
|
Knippertz I, Stein MF, Dörrie J, Schaft N,
Müller I, Deinzer A, Steinkasserer A and Nettelbeck DM: Mild
hyperthermia enhances human monocyte-derived dendritic cell
functions and offers potential for applications in vaccination
strategies. Int J Hyperthermia. 27:591–603. 2011.
|
|
16
|
Gagnier JJ, Kienle G, Altman DG, Moher D,
Sox H and Riley D; CARE Group. The CARE guidelines: consensus-based
clinical case report guideline development. J Clin Epidemiol.
67:46–51. 2014.
|
